Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 5/20 | 0.39 |
| ▸ | MTOR | P42345 | 2/20 | 0.35 |
| ▸ | RPTOR | Q8N122 | 2/20 | 0.35 |
| ▸ | MLST8 | Q9BVC4 | 2/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | TTK | P33981 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15031453 | 0.92 | DGAT1 (0.39) | DGAT1MTORRPTORMLST8GPR119 | |
| SCHEMBL15007518 | 0.88 | GRM4 (0.31) | DGAT1 | |
| SCHEMBL20938 | 0.87 | MTOR (0.39) | DGAT1MTORRPTORMLST8GPR119 | |
| SCHEMBL14298306 | 0.83 | DGAT1 (0.39) | DGAT1MTORRPTORMLST8 | |
| SCHEMBL19722 | 0.83 | GRM4 (0.32) | DGAT1 | |
| SCHEMBL15007529 | 0.83 | DGAT1 (0.31) | DGAT1 | |
| SCHEMBL15007530 | 0.83 | DGAT1 (0.31) | DGAT1 | |
| SCHEMBL15026300 | 0.83 | DGAT1 (0.31) | DGAT1 | |
| SCHEMBL2147969 | 0.83 | MTOR (0.46) | DGAT1MTORRPTORMLST8 | |
| SCHEMBL16229238 | 0.82 | MTOR (0.39) | MTORRPTORMLST8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883801-B2 | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883801-B2 | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-11-11 | — | — | US | disclosed |
| US-20130150362-A1 | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130150362-A1 | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150362-A1 | NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MTOR, RPS6KA5, PAK5 | DGAT1 1920/4885MTOR 1/4885RPTOR 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.